Company intelligence / Profile preview

Palate Therapeutics

Atlanta, Georgia, United Statespalatetx.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Palate Therapeutics is developing an oligonucleotide-based therapy that temporarily and reversibly alters how sweet foods are tasted and metabolized. In mouse models, a single dose led to up to 14 days of gene modulation in taste buds with minimal weight gain. The approach aims to prevent and manage metabolic diseases by changing food perception rather than food composition. The therapy may be used alone or combined with GLP-1 drugs.[1]

Therapeutic areas: ImmunologyMetabolic DisordersEndocrinologyCardiovascular
Modalities: Oligonucleotides[1]
Industry: Biotech

Beyond the preview

Go deeper on Palate Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Palate Therapeutics.

Explore the full profile